Veeva Systems (VEEV) Investor Day 2026 summary

Strategy and market opportunity

• Vision: complete the life-sciences industry cloud, connect the industry to sites, regulators, doctors, patients and partners, and deliver validated, industry-specific AI.

• Biopharma and MedTech represent a >$2T market growing 6%+; life-sciences TAM rose to $30B+ from $20B, largely on AI, with ~12% penetration.

• Portfolio spans 15 suites and ~60 products across applications, agents, data and consulting; Development is just under half of TAM, Quality ~20%, and Commercial 35%.

• The $6B 2030 revenue run-rate goal is on track; prior $1B 2020 and $3B 2025 goals were achieved. The goal is a long-term objective, not a forecast or CAGR.

Product and growth initiatives

• Study Suite targets a >$1B outsourced EDC, eCOA and RTSM opportunity; planned for Spring 2027, it will be supported by a dedicated team pursuing CROs.

• Clinical Network will connect research sites and sponsors; SiteVault eSource transfers site data from electronic records into EDC, reducing paper, cost and trial time.

• Veeva Basics provides standardized, validated Vault processes without configuration or implementation; nearly 200 biotechs use it.

• Aspen is developing a next-generation, cross-industry CRM platform and application with early adopters; designed for AI, speed, lower cost and usability, with internal use planned next year.

• IQVIA plans to move eTMF, CTMS and Site Connect live for all new studies in seven months; CRO adoption could support Study Suite distribution.

AI strategy and monetization

• Vault AI is optional, available within Vault with unlimited use, and priced at 10% of the relevant Vault subscription; releases follow a two-week cycle.

• Falcon provides agentic labor linked to Vault applications; agents are licensed annually by capability, with pricing varying by customer and agent.

• Falcon agents span clinical, regulatory, safety and commercial workflows, including TMF, study management, submissions, case management and MLR; early use includes MLR review and clinical document intake.

• Near-term Falcon focus is product excellence and customer success, with revenue secondary to proving value. The $6B goal excludes Falcon, Vault AI and Aspen, leaving potential contribution beyond the goal framework.

• AI-enabled services aim to deliver more work at fixed cost and accelerate implementations; Business Consulting is expected to drive services growth through 2030.